Ion Channel Pathophysiology: TRPM3 in ME/CFS

1 Cabanas et al. 2021 — Low-Dose Naltrexone Restores TRPM3 Function in NK Cells

Full Citation:: Cabanas H, et al. Low Dose Naltrexone Restores TRPM3 Ion Channel Function in {NK} Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Frontiers in Immunology. 2021;12. DOI:: 10.3389/fimmu.2021.684703 Published:: July 2021 Study Design:: In vitro mechanistic study using NK cells from ME/CFS patients and healthy controls Key Findings::

- Confirmed TRPM3 ion channel dysfunction in NK cells of ME/CFS patients
- Low-dose naltrexone (LDN) restores TRPM3 function in vitro
- TRPM3 is a calcium-permeable cation channel expressed on NK cells, sensory neurons, pancreatic $\beta$-cells, vascular smooth muscle, and brain
- Dysfunction impairs calcium influx required for NK cell degranulation and cytotoxic function

Relevance:: Establishes the mechanistic link TRPM3 dysfunction → impaired NK cell calcium signaling → ME/CFS pathophysiology, and identifies LDN as a therapeutic agent acting via this mechanism. Directly supports the TRPM3-calcium-mitochondria cascade hypothesis: impaired calcium influx through dysfunctional TRPM3 reduces mitochondrial calcium signaling, impairing ATP production under demand. Provides the first actionable therapeutic target from ion channel research in ME/CFS. Limitations:: In vitro study on isolated NK cells; mechanism by which LDN restores TRPM3 function not fully elucidated; clinical outcome data needed. Certainty Assessment::

- *Quality:* Moderate (in vitro; human NK cells)
- *Evidence base:* Mechanistic; confirmed by Cabanas 2024 and Sasso 2026

2 Cabanas et al. 2024 — Pathophysiological Role of TRPM3 in ME/CFS and LDN Therapeutic Effect

Full Citation:: Cabanas H, et al. Potential pathophysiological role of TRPM3 in {ME/CFS} and therapeutic effect of low-dose naltrexone. Journal of Translational Medicine. 2024;22:630. DOI:: 10.1186/s12967-024-05412-3 Published:: 2024 Study Design:: Original data plus mechanistic review Key Findings::

- Extends TRPM3 dysfunction beyond NK cells to sensory neurons, pancreatic $\beta$-cells, vascular smooth muscle, retinal ganglion cells
- Systemic TRPM3 channelopathy provides a unified explanation for multi-organ ME/CFS manifestations
- Confirms and extends LDN therapeutic effects on TRPM3 function
- Proposes TRPM3 as a candidate biomarker for ME/CFS subtyping

Relevance:: The systemic channelopathy framework explains how a single ion channel dysfunction produces the diverse ME/CFS symptom constellation: sensory hypersensitivity (sensory neurons), autonomic instability (vascular smooth muscle), glucose dysregulation (pancreatic \(\beta\)-cells), and cognitive impairment (brain). Provides mechanistic basis for TRPM3-SAMA connection: dysfunctional TRPM3 in sensory neurons may lower mast cell activation thresholds via abnormal neuropeptide release (substance P, CGRP). Limitations:: Direct demonstration of TRPM3 dysfunction in non-NK cell tissues in ME/CFS patients not yet completed for all proposed tissues. Certainty Assessment::

- *Quality:* Moderate (original data + review)
- *Currency:* Current (2024)

3 Sasso et al. 2026 — Multi-Site Validation of TRPM3 Dysfunction in ME/CFS

Full Citation:: Sasso EM, et al. Multi-site validation of TRPM3 ion channel dysfunction in {ME/CFS}. Frontiers in Medicine. 2026. Published:: January 2026 Study Design:: Multi-site validation across independent cohorts Key Findings::

- Independent replication across multiple sites of TRPM3 ion channel dysfunction in NK cells of ME/CFS patients
- Validates Cabanas 2021 and 2024 findings in geographically and methodologically independent cohorts
- Establishes TRPM3 NK cell dysfunction as a robust, reproducible finding

Relevance:: Multi-site replication is the highest available level of evidence for this mechanism in ME/CFS. Transforms a single-group finding into a robust, reproducible result. Supports using TRPM3 NK cell assays as a mechanistic endpoint in clinical trials. Validates the TRPM3 channelopathy hypothesis as a priority research and therapeutic target. Limitations:: Full publication details not available at time of writing; clinical outcome correlations and full therapeutic characterisation remain to be published. Certainty Assessment::

- *Quality:* High (multi-site validation, 2026)
- *Currency:* Very current (2026)
- *Evidence base:* Highest available level of evidence for TRPM3 in ME/CFS